Clinical trial · Observational
ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study
ALK Digital Pathology Outcome Prediction
NCT06846736CI-TRIAL-00086490ALKDigPathenrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Goal of this observational study is to develop an AI-driven pathologic image analysis-based classifier that can identify patients unlikely to significantly benefit from the currently utilized first-line ALK inhibitors (advanced-generation ALK inhibitors). Our goal is a classifier with final ROC-AUC value of 0.75.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| ALK-inhibitor Treated | — | UNRESOLVED | — |
| Alk-positive Non-Small Cell Lung Cancer | ALK-Positive Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- A classifier predicting outcome for advanced NSCLC ALK+ patients on ALK inhibitor treatment
- timeFrame
- 36 months
- description
- A classifier predicting outcome for advanced NSCLC ALK+ patients on ALK inhibitor treatment, based on AI analysis of digital pathology images of the diagnostic biopsy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient aged ≥ 18 years; * Patient with an oncologic disease; * ALK positive patients with advanced NSCLC that have received an advanced-generation ALK inhibitor treatment as the first ALK inhibitor (i.e. alectinib, lorlatinib, brigatinib or ceritinib) Exclusion Criteria: * Absence of information on the last oncologic treatment received; * Patient without a general or specific consent for this study
References
Publications (0)
Data not yet available
No reference posted for this study.